SAFETY DATA SHEET

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture	MEKINIST TABLETS
Registration number	-
Synonyms	TRAMETINIB TABLETS * TRAMETINIB AQUEOUS FILM COATED TABLETS * TRAMETINIB AQUEOUS FILM COATED TABLETS 0.25 MG - 2.0MG * GSK1120212B AQUEOUS FILM COATED TABLETS 0.25 MG - 2.0MG * TRAMETINIB, FORMULATED PRODUCT * GSK1120212B, FORMULATED PRODUCT
Issue date	22-October-2014
Version number	10
Revision date	22-October-2014
Supersedes date	12-September-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses	Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.
Uses advised against	No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.3. Other hazards Caution - Pharmaceutical agent. Avoid breaking or crushing tablets. Avoid breathing dusts from this material. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
TRAMETINIB	0.2 - 2.0	108-78-1 203-615-4	-	-	M=10
Classification: **DSD:** Repr. Cat. 3;R63, T;R48/25, R43, N;R50/53					
CLP: Skin Sens. 1;H317, Repr. 2;H361, STOT RE 1;H372, Aquatic Acute 1;H400, Aquatic Chronic 1;H410					
MAGNESIUM STEARATE	<1.0	557-04-0 209-150-3	-	-	
Classification: **DSD:** -					
CLP: -					
Titanium dioxide	<1.0	13463-67-7 236-675-5	-	-	
Classification: **DSD:** -					
CLP: -					
DODECYL SODIUM SULFATE	<0.1	151-21-3 205-788-1	-	-	
Classification: **DSD:** F;R11, Xn;R22, Xi;R36/38					
CLP: Flam. Sol. 1;H228, Acute Tox. 4;H302, Skin Irrit. 2;H315, Eye Irrit. 2;H319, STOT SE 3;H335					
Other components below reportable levels	>95.0				

List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.
DSD: Directive 67/548/EEC.
M: M-factor
vPvB: very persistent and very bioaccumulative substance.
PBT: persistent, bioaccumulative and toxic substance.
#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

4.1. Description of first aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control centre immediately. Do not induce vomiting without advice from poison control center.

4.2. Most important symptoms and effects, both acute and delayed May cause allergic skin reaction.
The following adverse effects have been noted with therapeutic use of this material: bone marrow toxicity; gastrointestinal distress; cardiovascular effects; symptoms of hypersensitivity (such as skin rash, hives, itching); fatigue; anaemia; skin changes. Additional effects of overexposure may occur.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing media Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media None known.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures Use water spray to cool unopened containers.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up Stop the flow of material, if this is without risk. Collect spillage. Prevent product from entering drains. Following product recovery, flush area with water.

6.4. Reference to other sections For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

SECTION 7: Handling and storage

7.1. Precautions for safe handling Avoid breaking or crushing tablets. Avoid breathing dusts from this material.
Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. Avoid release to the environment. Do not empty into drains.

7.2. Conditions for safe storage, including any incompatibilities Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Refrigeration recommended. Store away from incompatible materials (see Section 10 of the SDS).

7.3. Specific end use(s) Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Type	Value	Note
DODECYL SODIUM SULFATE (CAS 151-21-3)	OHC	2	
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1	
TRAMETINIB (CAS 108-78-1)	8 HR TWA	2 mcg/m3	
	OHC	4	SKIN SENSITISER
		4	Reproductive hazard

UK. EH40 Workplace Exposure Limits (WELs)

Components	Type	Value	Form
Titanium dioxide (CAS 13463-67-7)	TWA	4 mg/m3	Respirable.
		10 mg/m3	Inhalable

Biological limit values No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures Follow standard monitoring procedures.

Derived no-effect level (DNEL) Not available.

Predicted no effect concentrations (PNECs)	Not available.

8.2. Exposure controls

Appropriate engineering controls	General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

General information	Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.
Eye/face protection	Not normally needed. If contact is likely, safety glasses with side shields are recommended. (eg. EN 166)
Skin protection	
- Hand protection	Not normally needed. For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).
- Other	Not normally needed. Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for splashes, EN ISO 13982 for dust)
Respiratory protection	No personal respiratory protective equipment normally required. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387).
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.
Hygiene measures	For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. Consider control procedures for maintenance, cleaning and emergencies. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices.

Environmental exposure controls

Hazard guidance and control recommendations	Contain spills and prevent releases and observe national regulations on emissions. Environmental manager must be informed of all major releases. Avoid release to the aquatic environment. Wastewaters containing this material must be converted to non-hazardous forms and/or rendered biodegradable prior to discharge.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance	
Physical state	Solid.
Form	Tablet.
Colour	Not available.
Odour	Not available.
Odour threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Solubility (other)	Not available.

Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.
9.2. Other information	No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.
10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Contact with incompatible materials.
10.5. Incompatible materials	Strong oxidising agents. Fluorine.
10.6. Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Inhalation	Health injuries are not known or expected under normal use. Do not breathe dust/fume/gas/mist/vapors/spray.
Skin contact	Health injuries are not known or expected under normal use. May cause an allergic skin reaction.
Eye contact	Health injuries are not known or expected under normal use. Direct contact with eyes may cause temporary irritation.
Ingestion	Health injuries are not known or expected under normal use. May be harmful if swallowed.
Symptoms	May cause an allergic skin reaction. The following adverse effects have been noted with therapeutic use of this material: bone marrow toxicity; gastrointestinal distress; cardiovascular effects; symptoms of hypersensitivity (such as skin rash, hives, itching); fatigue; anaemia; skin changes. Additional effects of overexposure may occur.

11.1. Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use. May be harmful if swallowed.

Components	Species	Test results
DODECYL SODIUM SULFATE (CAS 151-21-3)		
Acute		
Oral		
LD50	Rat	1288 mg/kg
MAGNESIUM STEARATE (CAS 557-04-0)		
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
Titanium dioxide (CAS 13463-67-7)		
Acute		
Inhalation		
LC50	Rat	6820 mcg/m3
Oral		
LD50	Rat	> 24 g/kg
Chronic		
Inhalation		
LOEC	Rat	8.6 mg/m3, 1 years TiO2 accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.
NOAEC	Rat	250 mg/m3, 2 years Highest dose
		5 mg/m3, 24 months

Components	Species	Test results
Subacute		
Inhalation		
LOEL	Rat	0.1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m3, 3 weeks No evidence of significant inflammation in respiratory tract.
Oral		
NOAEL	Rat	100000 ppm, 14 Day Dietary study, highest dose tested.
Subchronic		
Inhalation		
LOEC	Rat	3.2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.
TRAMETINIB (CAS 108-78-1)		
Subacute		
Oral		
LD	Rat	1 mg/kg/day, 14 days
Subchronic		
Oral		
NOAEL	Dog	< 0.03 mg/kg/day, 13 weeks Gastro-intestinal lesions, bone marrow
	Rat	< 0.02 mg/kg/day, 13 weeks Stomach, Reduced corpora lutea

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use. Prolonged skin contact may cause temporary irritation.

Irritation Corrosion - Skin

TITANIUM DIOXIDE	0, Literature data Result: Non-irritant Species: Guinea pig 0, Literature data Result: Non-irritant Species: Human Acute dermal irritation; OECD 404, Literature data Result: Non-irritant Species: Rabbit
TRAMETINIB	Reconstituted Human Epidermis (RHE) Result: negative

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE	0

Serious eye damage/eye irritation Health injuries are not known or expected under normal use. Direct contact with eyes may cause temporary irritation.

Eye

TITANIUM DIOXIDE	OECD 405, Literature data Result: Mild irritant Species: Rabbit
TRAMETINIB	Reconstituted Human Corneal Epithelium (HCE) Result: negative

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE	4 Recovery Period: 2 days

Respiratory sensitisation Not available.

Skin sensitisation May cause an allergic skin reaction.

Sensitisation

TITANIUM DIOXIDE	5 % Optimisation Test, Literature data - Vehicle: petrolatum Result: negative Species: Guinea pig Test Duration: 48 hour exposure

Sensitisation

TRAMETINIB	OECD 429 / Local Lymph Node Assay, Maximum concentration = 1%; vehicle = acetone:olive oil 4:1; SI = 6.4 Result: positive Species: Mouse Occupational exposure Result: Positive (limited number of reported cases) Species: Human
TITANIUM DIOXIDE	Patch test, Literature data Result: negative Species: Human

Germ cell mutagenicity Health injuries are not known or expected under normal use.

Mutagenicity

TRAMETINIB	Ames Assay, GLP assay Result: negative
TITANIUM DIOXIDE	Ames, Literature data Result: negative Micronucleus Assay in vitro, CHO cells, Literature data Result: negative Micronucleus Assay in vitro, cultured human peripheral lymphocytes, Literature data Result: positive
TRAMETINIB	Micronucleus Assay, GLP assay; maximum dose = 2 mg/kg (oral MTD) Result: negative Species: Rat Mouse Lymphoma Cell (L5178Y) Mutation Assay, GLP assay Result: negative
TITANIUM DIOXIDE	Syrian Hamster Embryo (SHE) cell transformation assay Result: negative WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell lymphoblastoid, Literature data Result: positive

Carcinogenicity Health injuries are not known or expected under normal use. Contains a material (titanium dioxide) classified as a carcinogen by external agencies. Carcinogenic activity was seen in inhalation studies using laboratory animals. High concentrations or doses administered over an extended period of time were required to produce adverse effects.

TITANIUM DIOXIDE	0.5 mg/m3, Literature data Result: negative Species: Rat Test Duration: 24 months 0.72 - 14.8 mg/m3, Literature data Result: negative Species: Mouse 10 - 250 mg/m3, Dietary study - Literature data. Result: Inflammation at all doses with alveolar/bronchiolar adenoma at the highest concentration. Species: Rat Test Duration: 24 months 25000 - 50000 ppm, Dietary study Result: negative Species: Mouse 25000 - 50000 ppm, Dietary study - Literature data. Result: negative Species: Rat 7.2 - 14.8 mg/m3, Literature data Result: Lung tumour Species: Rat Test Duration: 24 months
TRAMETINIB	SAR / QSAR, DEREK, Lhasa, UK Result: negative

IARC Monographs. Overall Evaluation of Carcinogenicity

Titanium dioxide (CAS 13463-67-7)	2B Possibly carcinogenic to humans.

Reproductive toxicity The ingredient trametinib has caused adverse effects on the development of unborn offspring in animal studies.

Reproductivity

TRAMETINIB	Embryo-foetal development - Oral Result: Foetal NOAEL = 0.016 mg/kg/day; decreased foetal weight with doses >/= 0.031 mg/kg/day; no other foetal adverse effects or malformations Species: Rat

Reproductivity

TRAMETINIB

Embryo-foetal development - Oral
Result: Foetal NOAEL not identified; decreased foetal weight and ossification delays with doses >/= 0.039 mg/kg/day; maternal toxicity with dose = 0.039 mg/kg/day
Species: Rabbit
Fertility, Female
Result: Decreased corpora lutea and increased ovarian cysts (>/= 0.016 mg/kg/day, 13 week study)
Species: Rat
Fertility, Male, No effects on male reproductive organs (rats, dogs) in repeat dose studies to 13 weeks
Result: negative
Species: Rat

Specific target organ toxicity - single exposure None known.

Specific target organ toxicity - repeated exposure Causes damage to organs through prolonged or repeated exposure.

Aspiration hazard Not available.

Mixture versus substance information No information available.

Other information Not available.

SECTION 12: Ecological information

12.1. Toxicity No information is available about the potential of this product to produce adverse environmental effects. Contains a substance which causes risk of hazardous effects to the environment. The product contains a substance which may cause long-term adverse effects in the environment.

Components		Species	Test results
DODECYL SODIUM SULFATE (CAS 151-21-3)			
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	5.4 mg/l, 48 hours Static test
Fish	EC50	Rainbow trout (Adult Oncorhyncus mykiss)	4.6 mg/l, 96 hours Flow-through test
Chronic			
Algae	NOEC	Green algae (Desmodesmus subspicatus)	30 mg/l, 72 hours
Crustacea	NOEC	Ceriodaphnia dubia	0.88 mg/l, 7 days Flow-though Test
Fish	NOEC	Fathead minnow (Pimephales promelas)	3.8 mg/l, 28 days Flow-through test
MAGNESIUM STEARATE (CAS 557-04-0)			
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
Titanium dioxide (CAS 13463-67-7)			
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours Static test
TRAMETINIB (CAS 108-78-1)			
Aquatic			
Acute			
Algae	EC50	Green algae (Pseudokirchnereilla subcapitata)	> 0.045 mg/l, 72 hours Nominal, OECD 201
	NOEC	Green algae (Pseudokirchnereilla subcapitata)	0.045 mg/l, 72 hours
Chronic			
Crustacea	LOEC	Water flea (Daphnia magna)	> 0.045 mg/l, 21 days semi-static test , OECD 211
	NOEC	Water flea (Daphnia magna)	0.0146 mg/l, 21 days
Fish	Growth test LOEC	Fathead minnow (Juvenile Pimephales promelas)	0.0146 mg/l, 28 days Nominal, OECD 210

Components		Species	Test results
	Growth test NOEC	Fathead minnow (Juvenile Pimephales promelas)	0.0045 mg/l, 28 days

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability No data is available on the degradability of this product.

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE	17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE	210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE	77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-ready)

DODECYL SODIUM SULFATE	95 % OECD 301 B
MAGNESIUM STEARATE	95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE	50 %, 13 days

12.3. Bioaccumulative potential No data available.

Partition coefficient n-octanol/water (log Kow)

DODECYL SODIUM SULFATE	1.6
TRAMETINIB	4.04 (measured)

Bioconcentration factor (BCF)

MAGNESIUM STEARATE	> 9999 Estimated

12.4. Mobility in soil Not available.

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE	5.86 Estimated

Mobility in general Not available.

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. This material and its container must be disposed of as hazardous waste. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with local/regional/national/international regulations.

Special precautions Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

14.1. UN number UN3077

14.2. UN proper shipping name Environmentally hazardous substance, solid, n.o.s. (TRAMETINIB TABLETS)

14.3. Transport hazard class(es)

Class 9

Subsidiary risk -

Label(s) 9

Hazard No. (ADR)	90
Tunnel code	E
14.4. Packing group	III
14.5. Environmental hazards	No.
14.6. Special precautions for user	May be able to ship as an Excepted or Limited Quantity. Review all HazMat Table packaging exceptions and instructions to identify options. May not be subject to ADR; See SP 601.

IATA

14.1. UN number	UN3077
14.2. UN proper shipping name	Environmentally hazardous substance, solid, n.o.s. (TRAMETINIB TABLETS)
14.3. Transport hazard class(es)	9
Subsidiary class(es)	-
14.4. Packing group	III
14.5. Environmental hazards	No.
Labels required	Not available.
ERG Code	9L
14.6. Special precautions for user	May be able to ship as an Excepted or Limited Quantity. Review all HazMat Table packaging exceptions and instructions to identify options. ID 8000, Consumer Commodity, may apply. See Packing Instruction Y963.
Other information	
Cargo aircraft only	Allowed.
Additional Information:	
Passenger & cargo	Allowed.

IMDG

14.1. UN number	UN3077
14.2. UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (TRAMETINIB TABLETS)
14.3. Transport hazard class(es)	
Class	9
Subsidiary risk	-
14.4. Packing group	III
14.5. Environmental hazards	
Marine pollutant	No.
EmS	F-A, S-F
14.6. Special precautions for user	May be able to ship as an Excepted or Limited Quantity. Review all HazMat Table packaging exceptions and instructions to identify options. May be exempt from IMDG regulations.See SP 335.

May be able to ship as an Excepted or Limited Quantity. Review all HazMat Table packaging exceptions and instructions to identify options.
ID 8000, Consumer Commodity, may apply. See Packing Instruction Y963.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

ADR; IATA; IMDG

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations	The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.
National regulations	Young people under 18 years old are not allowed to work with this product according to the EU Directive 94/33/EC on the protection of young people at work. Follow national regulation for work with chemical agents.
15.2. Chemical safety assessment	No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations	Not available.
References	GSK Hazard Determination
Information on evaluation method leading to the classification of mixture	The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.
Full text of any statements or R-phrases and H-statements under Sections 2 to 15	R11 Highly flammable. R22 Harmful if swallowed. R36/38 Irritating to eyes and skin. R43 May cause sensitization by skin contact. R48/22 Harmful: danger of serious damage to health by prolonged exposure if swallowed. R48/25 Toxic: danger of serious damage to health by prolonged exposure if swallowed. R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R63 Possible risk of harm to the unborn child. H228 Flammable solid. H302 Harmful if swallowed. H315 Causes skin irritation.

H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H361 Suspected of damaging fertility or the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure.
H400 Very toxic to aquatic life.
H410 Very toxic to aquatic life with long lasting effects.

Revision information This document has undergone significant changes and should be reviewed in its entirety.

Training information Follow training instructions when handling this material.

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.